Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Localized lipohypertrophy during growth hormone therapy].

Henriette Mersebach1, Ulla F Feldt-Rasmussen

  • 1Medicinsk endokrinologisk klinik PE-2131, H:S Rigshospitalet, DK-2100 København ø.

Ugeskrift for Laeger
|April 18, 2002
PubMed
Summary

Growth hormone (GH) therapy can cause lipohypertrophy, a rare fat accumulation complication. Treatment adjustments should consider clinical effects, not just insulin-like growth factor I (IGF-I) levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023
Same author

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.

PloS one·2016
Same author

PATIENTS ACHIEVING GOOD GLYCEMIC CONTROL (HBA1c <7%) EXPERIENCE A LOWER RATE OF HYPOGLYCEMIA WITH INSULIN DEGLUDEC THAN WITH INSULIN GLARGINE: A META-ANALYSIS OF PHASE 3A TRIALS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2015
Same author

Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.

Diabetes care·2014
Same author

Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.

Drugs & aging·2013
Same author

A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial.

Journal of diabetes science and technology·2013

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Pharmacology

Background:

  • A 51-year-old woman with panhypopituitarism received growth hormone (GH) therapy.
  • Concurrent malnutrition and alcoholic liver disease impacted insulin-like growth factor I (IGF-I) synthesis and its role as a biomarker.

Observation:

  • Subcutaneous fat accumulation (lipohypertrophy) was observed during GH treatment.
  • Hepatic IGF-I synthesis was reduced due to malnutrition and liver disease, potentially compromising GH monitoring.

Findings:

  • Peripheral GH and IGF-I levels may have exceeded physiological ranges, leading to localized lipohypertrophy.
  • Lipohypertrophy is an unusual adverse event associated with GH therapy.

Implications:

  • GH treatment adjustments should integrate clinical assessment alongside IGF-I monitoring.
  • Close monitoring for adverse events like lipohypertrophy is crucial in GH therapy, especially when IGF-I levels are unreliable.

Related Experiment Videos